演題抄録

International Session

開催概要
開催回
第54回・2016年・横浜
 

膠芽腫治療の問題点と課題

演題番号 : IS7-4

[筆頭演者]
成田 善孝:1 

1:国立研究開発法人国立がん研究センター中央病院・脳脊髄腫瘍科

 

Glioblastoma has one of the worst prognoses among cancers, although temozolomide improved the 5 year overall survival rate of glioblastomas from 10% (Brain tumor registry of Japan 2001-2005) to 16% (2005-2008). One of the biggest reasons for the poor prognosis of glioblastoma is that more than half of patients have a Karnofsky performance status score of 70 or less. Other reasons are as follows: 2) most patients are aged ≥60 years; 3) the tumor grows immediately[A1] and invades the surrounding brain regions; 4) only 50-60% patients are eligible for gross total tumor resection; 5) local tumor control is poor and most patients develop recurrence about 10 months after initial treatment; 6) there are many complications associated with glioblastoma; 7) limited number of effective drugs; 8) treatment does not readily improve the quality of life in patients; 9) only 30-40% of patients are positive for biomarkers indicating a good prognosis; 10) many patients do not undergo treatment in a centralized hospital.
A combination of temozolomide and bevacizumab did not improve the overall survival of glioblastoma patients, although bevacizumab improved the performance status in some patients. One of the answers to solve these problems is an earlier diagnosis and initiation of treatment for glioblastoma patients. In this session, the current problems associated with treating glioblastoma and the future direction of its treatment are discussed.

前へ戻る